MA-EXAGRID
18.8.2020 14:02:10 CEST | Business Wire | Press release
ExaGrid ® today announced that CloudComputing.pt , Portugal’s premier enterprise cloud computing strategy provider, led Lusitania Seguros to install ExaGrid’s Tiered Backup Storage solution, which bolstered the insurance company’s data protection by increasing the capacity and variety of its data backups.
Lusitania emerged in the insurance market in 1986 as the first Insurance Company with 100% Portuguese capital. Since then, and over more than 30 years, it has always designed itself as a company with an eye on the future. A reliable partner in all situations, focusing on creating value for the national economy, in order to contribute decisively to the progress and well-being of the entire Portuguese society.
The IT staff at Lusitania had modernized its infrastructure and used Veeam to back up its VMware environment, but needed to add to that as the company’s data and backup needs grew. “We wanted to expand our Veeam solution and we also needed to back up more Oracle databases and file servers, but we didn’t have enough time in our backup window to add more backup jobs,” said Miguel Rodelo, senior systems engineer at Lusitania. “We decided to test new solutions, and started to request proofs of concept (POC) for different products.”
Rodelo and his enterprise IT provider, David Domingos, chief sales officer at CloudComputing.pt, had attended VMWorld 2018 in Barcelona, where they stopped by the ExaGrid booth at the conference to learn more about the tiered backup storage solution, and ended up requesting a POC. “We decided together to bet on the ExaGrid technology,” said Rodelo. “I said that if the technology is as good as it claims to be I will buy it, and my reseller said that if it was that good, he would tell every client in Portugal about it.
“ExaGrid was the last POC that we were analyzing, and it ended up being the fastest and easiest to implement, and compared to the other products we were looking into at the same time, it was clear that ExaGrid offered the best backup performance, especially when it came to our Oracle data. I expected ExaGrid to integrate well with Veeam, and it did, but when I saw that I can also use Oracle RMAN to make direct backups to ExaGrid, I decided to implement ExaGrid as our central data storage for backups,” said Rodelo.
After working with ExaGrid to deliver high-performance backup storage to his client at Lusitania, David Domingos is eager to recommend the tiered backup storage solution to more CloudComputing.pt clients. “One of the best features of the ExaGrid system is that the client doesn’t feel the impact of data deduplication because of the Landing Zone feature. When you look at traditional storage, you run into capacity issues, but ExaGrid’s deduplication resolves those issues. In addition, ExaGrid speaks all of the languages of the backup apps and software, so if a client is using multiple approaches, such as Veeam and Oracle RMAN, or even Commvault or Veritas, ExaGrid will support all of them. ExaGrid is versatile and that adds to the value it brings our clients.”
ExaGrid writes backups directly to a disk-cache Landing Zone, avoiding inline processing and ensuring the highest possible backup performance, which results in the shortest backup window. Adaptive Deduplication performs deduplication and replication in parallel with backups so that an RTO and RPO can be easily met. Available system cycles are utilized to perform deduplication and offsite replication for an optimal recovery point at the disaster recovery site. Once complete, the onsite data is protected and immediately available in its full undeduplicated form for fast restores, VM Instant Recoveries, and tape copies while the offsite data is ready for disaster recovery.
Read the complete Success Story to learn more about Rodelo’s experience using ExaGrid. ExaGrid’s published customer success stories and enterprise stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivaled customer support.
About CloudComputing.pt
CloudComputing.pt was founded in 2010 with the objective to provide services to the corporate market based on Cloud Computing, Mobility and Information Security. The motivation to work in these fields is based on the strategic view that the organization's efficiency is measured by the capacity to share business information in real time with the right people in a safe manner anywhere. This way we promote clients' continuous innovation and value, based on the following skills: UEM Security, Identity and Access Management, Cloud and On-Premise Security and Infrastructure.
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories .
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005277/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom